StockUS listing USBLSIFPINKHealthcareEarnings Deterioration

BLSIF(BLSIF) Stock Analysis | Healthcare

USD --+0.00%
Reward45Moderate
Risk40Moderate
75%Data
Strong 12994% profit margin · Revenue down 61% YoY
USD —+0.00 (+0.00%) Previous close · PINK
Market cap 9.74M
Reward Ratingⓘ45 Moderate reward assessment · 75% data coverage
Bottom 25% of stocksView factors
Risk Ratingⓘ40 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on BLSIF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is BLSIF?

engages in the product testing, safety assessment, and manufacturing services in the United Kingdom and internationally.

AI Brief Pro

The brief on BLSIF

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is BLSIF?

engages in the product testing, safety assessment, and manufacturing services in the United Kingdom and internationally. It serves cosmetics, consumer packaged and household goods, and nutraceutical industries. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 9.74M, and a P/E ratio of 1.5x.

Financial Highlights

Investment Breakdown

Growth
Growth trend is developing — watch for revenue consistency over upcoming quarters.
Profitability
Profitability metrics are mixed — margins may be under pressure.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Discount reflects uncertainty around future performance.

OpenBook Logo Analysis

Reward: Moderate (45)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta-0.072
Insider Activity
12M windowNo data
No insider activity data available for this ticker.